Dose Response Study of Lasofoxifene in Postmenopausal Women With Osteoporosis - Japanese Asian Dose Evaluation

• Status: Completed
• Trial end date: 2006-03-01
• Target enrollment: 0
• Participant gender: Female

Summary

To establish the optimal dose of lasofoxifene that is fully effective in increasing the BMD in postmenopausal Asian women.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Ligand Pharmaceuticals

Criteria

Inclusion Criteria:

• postmenopausal Asian women with osteoporosis defined by low BMD

Exclusion Criteria:

• Metabolic bone disease, use of other osteoporosis drugs or drugs interering with normal bone metabolism